Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncternal Therapeutics (ONCT) and 180 Life Sciences (ATNF)
August 11 2022 - 07:20AM
TipRanks
Analysts have been eager to weigh in on the Healthcare sector with
new ratings on Oncternal Therapeutics (ONCT – Research Report) and
180 Life Sciences (ATNF – Research Report). Oncternal Therapeutics
(ONCT) In a report released yesterday, Jason McCarthy from Maxim
Group reiterated a Buy rating on Oncternal Therapeutics, with a
price target of $3.50. The company's shares closed last Wednesday
at $1.12, close to its 52-week low of $0.69. According to
TipRanks.
https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncternal-therapeutics-onct-and-180-life-sciences-atnf?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Jan 2023 to Feb 2023
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Feb 2022 to Feb 2023